Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.
Aim(s): To assess the efficacy of the first and second re-challenge therapy of 90Y- and/or 177Lu-DOTATOC peptide receptor-targeted radionuclide therapy (PRRT) in patients with grade 1 or 2 neuroendocrine tumors (NET).
Materials and methods: In this single center retrospective analysis, patients with grade 1 or 2 recurrent or progressive inoperable bronchial or gastroenteropancreatic NET who were admitted for re-challenge 90Y- and/or 177Lu-DOTATOC were analyzed. Re-challenge PRRT was defined as subsequent treatment after initial PRRT (repeated referral to PRRT). The time interval between treatments served as surrogate endpoint for time to progression. For re-challenge PRRT, patients underwent one 90Y-and/or 1-2 177Lu-DOTATOC treatment cycles.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Susanne Aberle
To read results and conclusion, please login ...
Further abstracts you may be interested in